Compare iShares Global Tech ETF (IXN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Tango Therapeutics Inc. — how do they compare? iShares Global Tech ETF trades at $142.04 (market cap $9.75B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares Global Tech ETF is far larger — about 2.6× Tango Therapeutics Inc.'s market cap, and iShares Global Tech ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 48 Days and Tango Therapeutics Inc. for 0 Days on average.
| IXN | TNGX | |
|---|---|---|
Market Cap | $9.75B | $3.75B |
Volume | 365,991 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $32.90 |
52-Week Low | $95.76 | $7.50 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN (iShares Global Tech ETF) trades at $147.07, down 0.49% on the day but maintains a bullish technical signal with strong moving average support. The ETF recently hit a 52-week high, reflecting momentum despite current consolidation. Technical indicators show mixed signals with neutral RSI readings but bearish ADX trends, while support levels cluster around $146-147.
The outlook remains constructive given the ETF's exposure to global technology leaders and attractive valuation metrics. Key risks include concentration in tech stocks and AI sector volatility. Analyst sentiment appears positive with recent buy ratings citing compelling valuations and long-term growth potential in the global tech landscape.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
